This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I07 (Rheumatic tricuspid valve diseases) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Rheumatic tricuspid stenosis (I07.0), rheumatic tricuspid regurgitation (I07.1), rheumatic tricuspid stenosis with regurgitation (I07.2) |
| C. Adult onset | Rheumatic tricuspid stenosis is almost always accompanied by mitral stenosis and presents with symptoms of right heart failure in adults in their 30s to 50s. Isolated tricuspid involvement is very rare and appears as part of multivalvular disease. |
| 1. History | Tricuspid disease long regarded as secondary to the mitral valve. Active valve surgery applied since the 1970s–80s. Recent trend of renewed recognition of the clinical importance of the tricuspid valve. |
| 2. Causes | Rheumatic fever is almost the only cause of tricuspid stenosis. Tricuspid regurgitation also includes functional regurgitation due to pulmonary hypertension in addition to direct rheumatic involvement. |
| 3. Genetics | The HLA-associated immunogenetic susceptibility of rheumatic fever acts in the same way. No independent genetic factor for tricuspid involvement itself has been identified. |
| 4. General epidemiology | Tricuspid involvement in 10–30% of rheumatic heart disease. Isolated tricuspid stenosis is rare; most cases accompany mitral stenosis. Female predominance (about 4:1). Concentrated in low- and middle-income countries. |
| 5. Pathophysiology | Rheumatic endocarditis causes tricuspid leaflet fibrosis and commissural fusion. Increased right atrial–right ventricular pressure gradient leads to systemic venous congestion. Regurgitation arises from direct damage or functional causes. |
| 6. Symptoms | Jugular venous distension, hepatic congestion (right upper quadrant discomfort), ascites, lower extremity edema, fatigue. Kussmaul sign (paradoxical increase in jugular venous distension on inspiration). |
| 7. Signs | Prominent a-wave elevation in the jugular vein, low-pitched diastolic murmur (accentuated on inspiration), hepatic pulsation, ascites, jaundice. Tricuspid regurgitation: holosystolic murmur (accentuated on inspiration, Carvallo sign). |
| 8. Screening | Regular echocardiography including tricuspid assessment in patients with rheumatic heart disease. Immediate reassessment upon onset of right heart failure symptoms. Assessment of tricuspid regurgitation is essential at the time of left-sided valve surgery. |
| 9. Diagnosis | Echocardiography: valve morphology, tricuspid valve area, right atrial–right ventricular pressure gradient (Doppler), regurgitant jet. ECG: right atrial enlargement (P pulmonale). Pressure measurement by cardiac catheterization. |
| 10. Treatment | Diuretics, aldosterone antagonists (symptom relief). Severe tricuspid stenosis with regurgitation: surgical commissurotomy or valve replacement. Functional regurgitation: consider concomitant repair at the time of left-sided surgery. |
| 11. Prognosis | With severe tricuspid regurgitation, poor prognosis due to progression of right heart failure. In-hospital mortality of tricuspid surgery about 5–10% for isolated surgery. Outcomes improve when performed concomitantly with left-sided surgery. |
| 12. Prevention | Prevention of rheumatic recurrence with secondary prophylaxis (benzathine penicillin G). For functional tricuspid regurgitation, early treatment of left-sided heart disease is the key prevention strategy. |
| 13. References | Managing tricuspid valve pathology in multiple valvular heart disease … and 9 other papers |
Historically, tricuspid valve disease has received relatively less attention than mitral and aortic valve disease. Pathological studies in the late 19th and early 20th centuries confirmed that tricuspid involvement is not uncommon in patients with rheumatic heart disease, but clinically, symptoms of mitral valve disease were often in the foreground, so tricuspid involvement was frequently overlooked. Characteristic hemodynamic findings of tricuspid stenosis, such as prominent elevation of the jugular venous 'a' wave, were described in the late 19th century, but clinical recognition linking them to tricuspid disease was established in the early 20th century.
As open-heart surgery using cardiopulmonary bypass became widespread in the 1960s–70s, tricuspid surgery also began to be performed in earnest. Initially, tricuspid lesions were sometimes left untreated or only tricuspid valve excision was performed, but later surgical treatment became established as outcomes of tricuspid annuloplasty and replacement improved. With the development of De Vega commissurotomy, ring annuloplasty using the Carpentier ring, and others, the standard for tricuspid repair was established.
In the 21st century, awareness grew that tricuspid regurgitation contributes independently to cardiovascular prognosis. In the past, it was often expected that functional tricuspid regurgitation would improve spontaneously after correction of left-sided heart disease, but as long-term follow-up studies confirmed the poor prognosis of untreated severe tricuspid regurgitation, active treatment strategies began to be recommended. Recently, transcatheter tricuspid valve intervention (TTVI) is being developed and applied clinically as an alternative for patients at high surgical risk.
The cause of rheumatic tricuspid stenosis is almost entirely endocarditis due to rheumatic fever. Other causes of clinically significant tricuspid stenosis include carcinoid heart disease, congenital tricuspid stenosis, and lupus endocarditis (Libman-Sacks endocarditis), but these are very rare. Rheumatic tricuspid stenosis very rarely occurs in isolation and is almost always accompanied by rheumatic mitral stenosis.
Rheumatic tricuspid regurgitation occurs by two mechanisms. The first is organic regurgitation due to direct damage to the leaflets (fibrous thickening, retraction) by rheumatic endocarditis, and the second is functional regurgitation, in which pulmonary hypertension due to left-sided heart disease (mitral stenosis, heart failure, etc.) dilates the right ventricle and stretches the tricuspid annulus. In rheumatic heart disease, these two mechanisms often act in combination in tricuspid regurgitation.
The genetic basis of rheumatic tricuspid valve disease is the same as the immunogenetic factors that determine host susceptibility to rheumatic fever and rheumatic heart disease. Specific forms of HLA class II genes (especially HLA-DR7 and HLA-DRB1-related alleles) are associated with the occurrence of rheumatic fever and the severity of cardiac involvement, which indirectly affects tricuspid involvement as well. However, no independent genetic factor for specific involvement of the tricuspid valve has been identified to date.
There is a theoretical hypothesis that genetic factors affecting tricuspid annular size and right ventricular remodeling may be involved in the occurrence and severity of functional tricuspid regurgitation, but clinical genetic studies supporting this are still limited. Reports of familial tricuspid regurgitation are extremely rare, and genetic testing for tricuspid valve disease is not currently recommended routinely in clinical practice.
The frequency of tricuspid involvement in patients with rheumatic heart disease varies among studies, but clinically significant tricuspid disease is estimated to occur in 10–30% of all rheumatic heart disease. Isolated rheumatic tricuspid stenosis is very rare, and rheumatic mitral stenosis is present in more than 95% of cases. The frequency of tricuspid involvement is higher in multivalvular rheumatic heart disease.
Tricuspid stenosis is markedly more common in women than in men (about 4:1), consistent with the higher frequency of rheumatic fever and the greater prevalence of mitral stenosis in women. Worldwide, tricuspid stenosis is distributed mainly in regions of low- and middle-income countries with high prevalence of rheumatic fever. In developed countries, the main causes of tricuspid regurgitation are more often functional (secondary, due to left-sided heart disease) or degenerative (prolapse, infective endocarditis, etc.) rather than rheumatic.
Tricuspid regurgitation is a very common echocardiographic finding; mild tricuspid regurgitation is observed even in 65–85% of normal adults. However, the prevalence of moderate or greater tricuspid regurgitation is much lower, and in such cases it significantly affects clinical prognosis. Severe tricuspid regurgitation of rheumatic origin should be approached in the context of multivalvular disease.
The pathophysiology of rheumatic tricuspid stenosis is similar to that of mitral stenosis. With repeated rheumatic endocarditis, thrombi are deposited on the commissures of the three tricuspid leaflets (anterior, posterior, septal), and fibrous scars form during healing. As commissural fusion progresses, the tricuspid orifice area decreases and blood flow from the right atrium to the right ventricle is restricted. As a result, the right atrial–right ventricular pressure gradient rises, and when right atrial pressure increases, systemic venous pressure rises, causing systemic venous congestion (jugular venous distension, hepatic congestion, ascites, lower extremity edema).
Rheumatic tricuspid regurgitation occurs when the leaflets shorten due to fibrous retraction and complete closure becomes impossible. In functional tricuspid regurgitation, pulmonary hypertension due to left-sided heart disease (especially mitral stenosis) increases right ventricular afterload, dilating the right ventricle and stretching the tricuspid annulus, so that failure of leaflet coaptation results in regurgitation. In this case, the valve itself is structurally relatively normal but functionally unable to close.
The symptoms of rheumatic tricuspid stenosis are mainly due to systemic venous congestion. Patients complain of jugular venous distension, right upper quadrant discomfort or fullness (hepatic congestion), ascites, and lower extremity edema. Gastrointestinal symptoms such as anorexia, nausea, and weight gain may also occur. Fatigue and reduced exercise tolerance result from decreased cardiac output.
Symptoms of pulmonary venous hypertension (dyspnea, orthopnea) due to coexisting mitral stenosis often appear together. Interestingly, a paradoxical phenomenon may occur in which tricuspid stenosis restricts blood flow to the right ventricle, relatively alleviating the pulmonary edema symptoms caused by mitral stenosis. For this reason, tricuspid stenosis may go undiagnosed. When atrial fibrillation develops, symptoms worsen suddenly, and jaundice due to chronic venous congestion and, in severe cases, cardiac cirrhosis may also develop.
The most characteristic physical sign of tricuspid stenosis is prominent elevation of the 'a' wave in the jugular venous waveform. This is because right atrial pressure rises markedly when the right atrium pushes blood through the narrowed tricuspid valve. When atrial fibrillation is present, the 'a' wave disappears. On auscultation, a low-pitched diastolic murmur is heard in the tricuspid area (left lower sternal border), characteristically with increased murmur intensity on inspiration (a form similar to the Carvallo sign). This is because venous return increases on inspiration, increasing right heart flow.
Abdominal examination reveals hepatomegaly and ascites, and a pulsatile liver surface (hepatic pulsation) is a sign of tricuspid regurgitation. Bilateral pitting edema of the lower extremities appears, and long-standing edema may cause skin thickening or pigmentation. In tricuspid regurgitation, the Carvallo sign, in which the holosystolic murmur is accentuated on inspiration, is typical. Jaundice due to chronic hepatic congestion may also be observed.
Screening for tricuspid involvement in patients with rheumatic heart disease is part of regular echocardiographic follow-up performed together with assessment of the mitral and aortic valves. Because tricuspid stenosis can be difficult to detect by auscultation, it is important to assess the tricuspid valve as well by echocardiography in patients with rheumatic heart disease. In particular, tricuspid stenosis should be actively suspected when right heart failure symptoms are disproportionately severe relative to the severity of left-sided heart disease.
In functional tricuspid regurgitation, accurate assessment of the severity and anatomy of tricuspid regurgitation is essential in patients whose left-sided valve disease (especially mitral stenosis) is at the surgical planning stage. This is important for deciding whether to perform concomitant tricuspid repair at the time of left-sided surgery. Measurement of the tricuspid annular diameter and assessment of regurgitant jet severity on echocardiography are key.
Echocardiography is key for diagnosis and severity assessment. On two-dimensional echocardiography, thickening and reduced mobility of the tricuspid leaflets, commissural fusion, and doming are characteristic of stenosis. Doppler echocardiography measures the mean right atrial–right ventricular pressure gradient, and a mean gradient >5mmHg suggests significant tricuspid stenosis. Tricuspid valve area is calculated by the pressure half-time method (PHT: TVA = 190/PHT), and less than 1.0cm² indicates severe stenosis.
The severity of tricuspid regurgitation is assessed by the width of the regurgitant jet (vena contracta), regurgitant velocity, effective regurgitant orifice area (EROA) by the PISA method, and the presence of systolic flow reversal in the hepatic veins. EROA ≥0.40cm² is judged as severe regurgitation. On ECG, P-wave abnormalities (right atrial enlargement, P pulmonale: peaked P waves), findings of right ventricular hypertrophy, and atrial fibrillation may be observed. Chest X-ray shows right atrial enlargement, dilatation of the superior vena cava, pleural effusion, and the like. Cardiac catheterization is performed when echocardiographic results are unclear or preoperative coronary assessment is needed.
Medical treatment of rheumatic tricuspid stenosis is limited to symptom relief. Diuretics (loop diuretics, thiazides) and aldosterone antagonists (spironolactone) reduce systemic venous congestion (edema, ascites), together with salt restriction and fluid management. With atrial fibrillation, heart rate control and warfarin-based anticoagulation are needed.
Surgical treatment is considered for symptomatic severe tricuspid stenosis or when regurgitation coexists. In rheumatic tricuspid stenosis, surgical tricuspid commissurotomy is possible if valve anatomy is favorable, but tricuspid valve replacement (TVR) is needed when regurgitation coexists or valve damage is severe. Percutaneous balloon tricuspid valvuloplasty is technically feasible but may worsen pre-existing regurgitation, so caution is needed when rheumatic regurgitation is present.
In functional tricuspid regurgitation, concomitant tricuspid annuloplasty is recommended at the time of left-sided valve surgery (e.g., mitral commissurotomy or replacement). Tricuspid repair is performed together with left-sided surgery for severe (EROA ≥0.40cm²) tricuspid regurgitation, or even for moderate tricuspid regurgitation if the annular diameter is ≥40mm (Class IIa). Transcatheter tricuspid valve intervention (TTVI) is currently at the clinical trial stage and is being developed as an alternative for patients at high surgical risk.
Rheumatic tricuspid stenosis alone is not fatal, but if untreated, chronic systemic venous congestion leads to complications such as congestive cardiac cirrhosis, renal failure, and nutritional deficiency, resulting in poor long-term prognosis. Severe tricuspid regurgitation is independently associated with cardiovascular mortality, and this holds even when left heart function is preserved.
In-hospital mortality of tricuspid surgery is about 5–10% for isolated surgery, and the prognosis is worse when right ventricular dysfunction precedes it. When tricuspid repair is performed concomitantly with left-sided valve surgery, in-hospital mortality increases somewhat, but it is recommended because it prevents long-term worsening of prognosis from residual tricuspid regurgitation. When a mechanical valve is used for tricuspid replacement, the risk of thrombus formation in the tricuspid position is higher than in the mitral position, so thorough anticoagulation management is essential. Overall, 10-year survival after multivalve surgery is about 60–70%.
In preventing rheumatic tricuspid valve disease, the most important measure is preventing rheumatic recurrence and cumulative progression of valve damage through secondary prophylaxis of rheumatic fever (regular benzathine penicillin G). For functional tricuspid regurgitation, early diagnosis and appropriate treatment (PBMV or surgery) of left-sided heart disease, especially rheumatic mitral stenosis, prevents pulmonary hypertension and right ventricular overload and thus prevents worsening of tricuspid regurgitation. In patients with severe tricuspid regurgitation, performing tricuspid repair concomitantly at the time of left-sided surgery can prevent long-term worsening of tricuspid regurgitation.
Taramasso M, Vanermen H, Maisano F, et al. The growing clinical importance of secondary tricuspid regurgitation. Journal of the American College of Cardiology. 2012;59(8):703-710. DOI: 10.1016/j.jacc.2011.09.069. PMID: 22340264.
Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. European Heart Journal – Cardiovascular Imaging. 2013;14(7):611-644. DOI: 10.1093/ehjci/jet105. PMID: 23733442.
Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. Journal of the American College of Cardiology. 2004;43(3):405-409. DOI: 10.1016/j.jacc.2003.09.036. PMID: 15013122.
Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criterion for surgical repair? Annals of Thoracic Surgery. 2005;79(1):127-132. DOI: 10.1016/j.athoracsur.2004.06.057. PMID: 15620928.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632. DOI: 10.1093/eurheartj/ehab395. PMID: 34453165.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2021;77(4):e25-e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.
Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet. 2009;374(9697):1271-1283. DOI: 10.1016/S0140-6736(09)60994-6. PMID: 19747723.
Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). American Journal of Cardiology. 1999;83(6):897-902. DOI: 10.1016/S0002-9149(98)01064-9. PMID: 10190406.
Agricola E, Asmarats L, Maisano F, et al. Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. Nature Reviews Cardiology. 2021;18(8):538-553. DOI: 10.1038/s41569-021-00518-z. PMID: 33785898.
Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation. 2005;112(23):3584-3591. DOI: 10.1161/CIRCULATIONAHA.105.539197. PMID: 16330697.